RecallRadar

FDA Drug recall D-0088-2023

Quinapril Tablets USP, 40 mg (90 pack), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc

On 2022-12-28 the FDA classified a Class II recall of Quinapril Tablets USP, 40 mg (90 pack), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc by Lupin Pharmaceuticals, citing CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0088-2023
ClassificationClass II
Statusterminated
Initiated2022-12-07
Published2022-12-28
Last updated2026-09-13 11:52 UTC
CompanyLupin Pharmaceuticals
DistributionUS

Product

Quinapril Tablets USP, 40 mg (90 pack), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, by: Lupin Limited, Goa 403 722 India, NDC# 68180-554-09

Reason

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Identifiers

ndc68180-556-09
ndc68180-557-09
ndc68180-557-03
ndc68180-558-09
ndc68180-558-03
ndc68180-554-09
ndc68180-554-03
ndc68180-559-03
ndc68180-559-09
code_infoLot #: G100533, G100534, Exp. 12/2022; G203071, Exp. 03/2024

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0088-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.